Medtronic receives regulatory warning

Medtronic one of the world’s leading medical device companies, has been hit by a warning letter from the regulatory Food and Drug Administration (FDA) in America which could delay the launch of the company’s new MiniMed 780G insulin pump. The FDA criticised Medtronic’s procedures for product recalls, complaint handling, quality systems and risk assessment following an inspection of the diabetes group headquarters in California last July. Six months on no meeting has been organised with Medtronic executives to agree the steps required to rectify the identified problems. Meanwhile Medtronics is not recommending any action by doctors or patients as a result of the warning letter.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags